Enhancement of rigidity by contralateral activation may aid in early detection of the disease. Medication reduced rigidity with and without contralateral activation. Increased rigidity with contralateral activation is not due to ipsilateral muscle activation.
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Enhancement of rigidity by contralateral activation may aid in early detection of the disease. Medication reduced rigidity with and without contralateral activation. Increased rigidity with contralateral activation is not due to ipsilateral muscle activation.
a b s t r a c t
Objective: Quantify the enhancement of parkinsonian rigidity associated with a contralateral activation maneuver. Methods: Twelve subjects with PD and eight controls participated in the study protocol. Subjects' tested hand was displaced by a servo-motor throughout wrist flexion and extension motions of 60°without and with a concurrent gripping activation in the contralateral hand, referred to as Passive and Active conditions, respectively. Subjects with PD were tested in both OFF-MED and ON-MED states. Rigidity was quantified by integrating torque with position during both flexion and extension (torque resistance). ANOVA was performed to assess the effect of contralateral activation on rigidity. Results: PD patients had significantly (0.038) enhanced torque resistance in OFF-MED compared to healthy controls and ON-MED. In the Active condition, differences in torque resistance were magnified (p = 0.002). Medication substantially reduced differences in torque resistance between controls and PD patients in the Passive and Active conditions. Conclusions: A contralateral activation maneuver substantially increases rigidity in patients with PD, specifically the OFF-MED state. Rigidity is reduced with the application of dopaminergic medication, even with the presence of a contralateral activation maneuver. Significance: These data support the use of a contralateral activation maneuver as a tool in the diagnosis of PD. Ó 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
Introduction
Parkinsonian rigidity is described as increased, uniform resistance to passive limb movement throughout the range of motion (Fung and Thompson, 2002) . Rigidity is a cardinal symptom of Parkinson's disease (PD), thereby used as a diagnostic criterion. According to the Motor Examination of the unified Parkinson's disease rating scale (UPDRS), assessment of rigidity, in clinic, ''is judged on slow passive movement of major joints with the patient in a relaxed position and the examiner manipulating the limbs and neck. If no rigidity is detected, ask the patient to perform an activation maneuver (e.g., tapping fingers, fist opening-closing or heel tapping in a limb not being tested) '' (Fahn and Elton, 1987) . The rationale for the incorporation of an activation maneuver lies in that activation maneuver performed by the contralateral hand may enhance the degree of rigidity, as rigidity is not easily detectable in the early stage of the disease. However, the notion about the effect of contralateral activation on parkinsonian rigidity is empirical because its effect has never been quantitatively examined. The current study was conducted to quantify the effect of contralateral activation on parkinsonian rigidity. The wrist joint was chosen because it is commonly evaluated for rigidity in clinical practice (Fung and Thompson, 2002) .
In addition to being used for a diagnostic purpose, rigidity is also used as a means of evaluating the efficacy of treatment, because it generally responds positively to therapeutic interventions. Dopaminergic medication and deep brain stimulation have been shown to reduce movement impairments associated with PD, such as rigidity, and directly affect the supraspinal coordina-
